Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS
Contenido archivado el 2024-05-29

Molecular Oncology Early Research Training

Objetivo

The aim of this proposal is to provide interdisciplinary training for early stage researchers in state-of-the-art molecular oncology. The recent growth of proteomics, genomics and other large-scale approaches has generated an enormous wealth of data that has transformed cancer research. Current cancer research is thus a multidisciplinary field of research involving disciplines such as biology, medicine, computer sciences, physics and chemistry, for example. However, the new strategies and experimental technologies not only have generated a stream of novel data, but in addition they have created an unprecedented demand for scientists with ample cross-disciplinary training in the various fields involved in cancer research. Addressing this urgent demand, the ONCO-TRAIN programme has the strategic objective to offer a comprehensive and highly multidisciplinary training programme in molecular oncology. Eight 3-year fellowships will be offered to perform Ph.D. studies in molecular pathology, molecular oncology, structural biology, experimental therapeutics and biotechnology. The research training is accompanied by complementary training designed to the needs of early stage researchers with the aim to strengthen the development of additional skills and to widen their career development prospects. This comprehensive and integrative training programme will contribute to the creation of a new European cadre of molecular cancer researchers with technical excellence, originality and breadth of vision.

Ámbito científico (EuroSciVoc)

Palabras clave

Tema(s)

Convocatoria de propuestas

FP6-2002-MOBILITY-2
Consulte otros proyectos de esta convocatoria

Régimen de financiación

EST - Marie Curie actions-Early-stage Training

Coordinador

FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III
Aportación de la UE
Sin datos
Coste total
Sin datos